(Q33571905)

28 July 2017

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. (English)

1 reference

28 July 2017

Bianca Weinstock-Guttman

10

object named as

Bianca Weinstock-Guttman

1 reference

28 July 2017

5

Hans-Peter Hartung

1 reference

28 July 2017

7

Ludwig Kappos

1 reference

28 July 2017

4

Ralf Gold

1 reference

28 July 2017

2

Bruce A C Cree

1 reference

28 July 2017

Robert J Fox

1

1 reference

28 July 2017

Jerome De Sèze

3

1 reference

28 July 2017

Douglas Jeffery

6

1 reference

28 July 2017

Michael Kaufman

8

1 reference

28 July 2017

Xavier Montalbán

9

1 reference

28 July 2017

Britt Anderson

11

1 reference

28 July 2017

Amy Natarajan

12

1 reference

28 July 2017

Barry Ticho

13

1 reference

28 July 2017

Petra Duda

14

1 reference

28 July 2017

RESTORE

15

1 reference

28 July 2017

language of work or name

English

0 references

publication date

28 March 2014

1 reference

28 July 2017

8

1 reference

inferred from page(s)

published in

Neurology

1 reference

28 July 2017

82

1 reference

28 July 2017

17

1 reference

28 July 2017

1491-1498

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011468

Switching from natalizumab to fingolimod: an observational study

31 October 2018

1 reference

12 December 2020

Natalizumab dosage suspension: are we helping or hurting?

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

12 December 2020

Observations during an elective interruption of natalizumab treatment: a post-marketing study

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

1 reference

12 December 2020

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

12 December 2020

Risk stratification and patient counseling for natalizumab in multiple sclerosis

1 reference

12 December 2020

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

1 reference

12 December 2020

10.1212/WNL.0000000000000355

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference